Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 12.66% | 6.76% | 23.34% | 16.26% | -29.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.04% | -14.34% | 0.00% | 1.70% | -29.21% |
| Operating Income | 18.86% | 23.04% | 0.03% | -2.89% | 39.26% |
| Income Before Tax | -90.75% | -34.64% | -35.28% | -66.43% | -157.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.75% | -34.64% | -35.28% | -66.43% | -157.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.75% | -34.64% | -35.28% | -66.43% | -157.78% |
| EBIT | 18.86% | 23.04% | 0.03% | -2.89% | 39.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -9.20% | -17.84% | -28.91% | -42.46% | -153.74% |
| Normalized Basic EPS | -9.13% | -10.92% | -20.92% | -34.15% | -147.01% |
| EPS Diluted | -9.20% | -17.84% | -28.91% | -42.46% | -153.74% |
| Normalized Diluted EPS | -9.13% | -10.92% | -20.92% | -34.15% | -147.01% |
| Average Basic Shares Outstanding | 163.27% | 96.03% | 56.15% | 33.78% | 32.18% |
| Average Diluted Shares Outstanding | 163.27% | 96.03% | 56.15% | 33.78% | 32.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |